TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05127434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05712616
Drug: Lacto-N-Hexaose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo look alike drug
Study: NCT02389933
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
Study: NCT05645315
Drug: TQB2618 injection and TQB2450 injection
Normalized name: INFLAMMATION AND INFECTION DETECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2618 is a TIM-3 receptor monoclonal antibody; TQB2450 is a new sequence of innovative anti-PD-L1 fully humanized monoclonal antibody;
Study: NCT05937191
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid Treatment
Study: NCT05261360
Drug: SF-MSC-EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
Study: NCT04875585
Drug: Adjuvant Treatment Phase
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with 15 cycles of Pembrolizumab
Study: NCT05295043
Drug: (CDK)4/6 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
Study: NCT04967950
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate
Study: NCT05044962
Drug: NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
Study: NCT04476277
Drug: Biotin label
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
Study: NCT05078827
Drug: Test Product (A): Fluorouracil Cream, 5% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Study: NCT05078827
Drug: Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Study: NCT05078827
Drug: Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
Study: NCT05737160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an SC infusion
Study: NCT05357950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matches active drug in size, color and taste
Study: NCT04834427
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Study: NCT05421195
Drug: corticosteroids therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids
Study: NCT05028140
Drug: PIEMONTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piemonte association 1 coated tablet once a day
Study: NCT04387617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
Study: NCT06651593
Drug: SAR444881
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05318755
Drug: GAHT for transgender women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Study: NCT04937738
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m², d1, i.v., every 2 weeks
Study: NCT04937738
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2600 mg/m²d1 i.v. every 2 weeks
Study: NCT04937738
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² two times per day (BID), d1-14
Study: NCT04926701
Drug: ETD001 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of inhaled ETD001
Study: NCT04926701
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of inhaled placebo
Study: NCT04926701
Drug: ETD001 multiple twice daily doses
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascending doses of inhaled ETD001 administered twice daily
Study: NCT04926701
Drug: Placebo multiple twice daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of inhaled placebo administered twice daily
Study: NCT04926701
Drug: ETD001 multiple once daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of inhaled ETD001 administered once daily
Study: NCT04926701
Drug: Placebo multiple once daily doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of inhaled placebo administered once daily
Study: NCT04801368
Drug: Randomization of two local anesthetics.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
Study: NCT04671407
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic Saline 3% and 0.9%
Study: NCT05870540
Drug: BPL-003
Normalized name: BANDAGE KIT,COMPRESSION LYMPHEDEMA#BPLEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered intranasally
Study: NCT05341856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
Study: NCT05077501
Drug: ACD856
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
Study: NCT05077501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT06495047
Drug: Long-acting bronchodilator therapy (LABD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting inhaler therapy
Study: NCT06495047
Drug: Short-acting bronchodilator therapy (SABD)
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting inhaler therapy
Study: NCT06106152
Drug: WTX212A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The WTX212A infusion is given every 21 days
Study: NCT06106152
Drug: PD -1/PD-L1 monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PD -1/PD-L1 monoclonal antibody is given every 21 days
Study: NCT05156086
Drug: COVID-19 vaccine, booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional dose of COVID-19 vaccine (booster shot)
Study: NCT05548231
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05548231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04665206
Drug: VT3989
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25, 50, 100,150 or 200 mg capsules for oral administration.
Study: NCT06476704
Drug: Administration of L-TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
Study: NCT05685225
Drug: Stage 1: Naltrexone/Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination
Study: NCT05685225
Drug: Stage 1: Acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone
Study: NCT05685225
Drug: Stage1: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05685225
Drug: Stage 2: Naltrxone/Acetaminophen low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination low dose
Study: NCT05520944
Drug: ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
Study: NCT05955326
Drug: Sovateltide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
Study: NCT05562466
Drug: QMF149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 75/40 μg o.d via Breezhaler
Study: NCT04286295
Drug: Nicoderm C-Q Transdermal Product
Normalized name: Nicoderm C-Q Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
Study: NCT04286295
Drug: Nicorette Lozenge Product
Normalized name: Nicorette Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
Study: NCT05580887
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1 Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study: NCT05580887
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
Study: NCT06679387
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: A once daily matched tablet of placebo for 12 weeks
Study: NCT04836182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-AGT-LRx-matching placebo will be administered by SC injection.
Study: NCT04792580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
Study: NCT02190786
Drug: KUX-1151
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05695417
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Injection of OTX-TKI
Study: NCT06039826
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05355207
Drug: TRL1068
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Study: NCT06483737
Drug: Ornithine Aspartate
Normalized name: Ornithine aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.
Study: NCT06267183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ： single-dose
Study: NCT06483737
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.
Study: NCT05647291
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/1ml methylprednisolone, two sessions once a week
Study: NCT04610580
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1840 will be administered orally.
Study: NCT05692934
Drug: HR20031 FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
Study: NCT05692934
Drug: HR20031 FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
Study: NCT05692934
Drug: HR20031 FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
Study: NCT05692934
Drug: HR20031 FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
Study: NCT05298254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.
Study: NCT05660772
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-articular knee injection of corticosteroid
Study: NCT04386980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent in normal saline
Study: NCT06394492
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin dose 2
Study: NCT06039774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06622486
Drug: EGL-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: NCT06125002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ingestion will occur orally, under monitoring by the responsible investigator.
Study: NCT05908695
Drug: GV-971
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered PO
Study: NCT05908695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered PO
Study: NCT06458257
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT05741502
Drug: Antipsychotics,Other (non-Clozapine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will assess monitor inflammatory/immune marker lab
Study: NCT06097702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo across Part 1 and 2 of the study.
Study: NCT05132439
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched to active study drug
Study: NCT06141590
Drug: administration of UIC202205, UIC202206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference
Study: NCT05455788
Drug: Aminoglycoside
Normalized name: Aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of sewing ring of prosthetic valve with aminoglycoside
Study: NCT04931862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial cerebrospinal fluid (aCSF)
Study: NCT05104892
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT05065541
Drug: [18F]T-401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06406010
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered in a pericapsular nerve group (PENG) block
Study: NCT05735028
Drug: Centipeda minima+PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
Study: NCT05735028
Drug: PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitor
Study: NCT06678399
Drug: KELI-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: KELI-101 consists of ex vivo expanded placental mesenchymal stromal cells (PMSCs) in a 10% cryopreservation solution.
Study: NCT05141786
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT06616077
Drug: Oral Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
Study: NCT06616077
Drug: Placebo Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa butter
Study: NCT06662760
Drug: TQB3002 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
Study: NCT06661694
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 875 mg dose of mevrometostat standard tablet formulation
Study: NCT06661694
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 875 mg dose of mevrometostat alternative tablet formulation
Study: NCT06090890
Drug: Lipid-lowering drug
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
Study: NCT05668455
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drops 4 times a day
Study: NCT06660420
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT06659757
Drug: KIT2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIT2014 will be administered by inhalation with a nebuliser
Study: NCT05746143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two days preoperatively and five days postoperatively
Study: NCT06659263
Drug: RE104 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, subcutaneous dose of RE104 for Injection
Study: NCT04614714
Drug: Nicotinamide riboside chloride
Normalized name: Nicotinamide Riboside Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
Study: NCT04614714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
Study: NCT06660719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study: NCT06659549
Drug: GAL-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval
Study: NCT06659549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
Study: NCT06595004
Drug: HCP1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug
Study: NCT06595004
Drug: RLD2401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT06661733
Drug: AZD5462
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD5462 orally.
Study: NCT05972564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consists of gelatin capsules.
Study: NCT00484991
Drug: Sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
Study: NCT05148533
Drug: TJ1133 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
Study: NCT06253117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05626387
Drug: Mycophenolate Mofetil plus prednisolone
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.